The Board of Directors of the Company considered and took on record the Unaudited Standalone and Consolidated Financial results of the company for the quarter ended June 30, 2025. Pursuant ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
The Board of Directors of GKB Ophthalmics Ltd, held on August 14, 2025, approved the unaudited standalone and consolidated financial results for Q1 FY26. On a consolidated basis, revenue from operations rose to Rs. 3,230.51 lakhs, up about 24% from Rs. 2,601.76 lakhs in the same quarter last year, but the company posted a loss after tax of Rs. 64.07 lakhs (vs profit of Rs. 10.50 lakhs in Q1 FY25). Standalone revenue was Rs. 877.49 lakhs (vs Rs. 861.90 lakhs YoY) with a wider loss after tax of Rs. 214.30 lakhs (vs Rs. 140.73 lakhs YoY), translating to a standalone EPS of Rs. (4.25). The auditor, MSKA & Associates, issued an unmodified limited review report. The Board also noted an ongoing labour dispute from 2009 where the company is challenging an Industrial Tribunal award in the Bombay High Court at Goa, with the next hearing fixed for further arguments.
Despite strong consolidated revenue growth, the company continues to post losses at both standalone and consolidated levels, indicating margin pressure and profitability concerns for shareholders. Investors should monitor whether revenue growth translates into profit improvement in upcoming quarters; the ongoing legal labour matter remains a potential contingent liability overhang.